- Insys Therapeutics (INSY -7%) Q4 results: Revenues: $66.5M (+65.4%); COGS: $5.9M (+13.5%); R&D Expense: $12.9M (+303.1%); SG&A: $31.6M (+81.6%); Operating Income: $16.1M (+11.8%); Net Income: $9.3M (-61.4%); EPS: $0.25 (-62.7%).
- FY2014 results: Revenues: $222.1M (+123.7%); COGS: $22.6M (+78.0%); R&D Expense: $33.1M (+289.4%); SG&A: $102.4M (+124.6%); Operating Income: $64M (+96.3%); Net Income: $38M (-5.9%); EPS: $1.04 (-26.2%); Quick Assets: $58.1M (+26.9%).
- No guidance given.